Inovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome.
According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The agreement also includes options to establish stockpiles of both vaccines, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio snags $56m award for Lassa fever, MERS vaccines appeared first on MassDevice.
from MassDevice https://ift.tt/2GPgVU8
Cap comentari:
Publica un comentari a l'entrada